Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients

Acute myeloid leukemia (AML) is widely considered a distinct clinical entity with a well-defined molecular and genetics-based prognosis. Particularly in a younger patient, the therapeutic approach depends largely on diagnostic risk stratification, which has an impact on the outcome after therapy. We...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Delia, Paola Carluccio, Anna Mestice, Claudia Brunetti, Francesco Albano, Giorgina Specchia
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2018/9325261
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566683593605120
author Mario Delia
Paola Carluccio
Anna Mestice
Claudia Brunetti
Francesco Albano
Giorgina Specchia
author_facet Mario Delia
Paola Carluccio
Anna Mestice
Claudia Brunetti
Francesco Albano
Giorgina Specchia
author_sort Mario Delia
collection DOAJ
description Acute myeloid leukemia (AML) is widely considered a distinct clinical entity with a well-defined molecular and genetics-based prognosis. Particularly in a younger patient, the therapeutic approach depends largely on diagnostic risk stratification, which has an impact on the outcome after therapy. We added Treg evaluation to the usual molecular and cytogenetics profile in the AML younger patients’ diagnostic bone marrow aspirate (dBMA) in order to search for any correlation between Tregs and overall response (OR) as well as survival (OS) rates. We studied 23 AML young patients, all treated with standard induction chemotherapy: OR (complete remission (CR) + CR incomplete (CRi)) was documented in 10 of 23 patients (44%); there were two partial responder patients. The optimal dBMA Treg cut-off value for predicting response to treatment (≥21/μL) was obtained by ROC curve analysis. However, in multivariate analysis, apart from the expected impact of the molecular/cytogenetic risk (p=0.049) and NPM mutation (p=0.001), dBMA Tregs ≥ 21/μL was not correlated with OR. Actually, higher dBMA Tregs were associated with the good intermediate molecular/cytogenetic risk group (p=0.02), whose median OS was confirmed to be better as compared with that of the poor risk group (18 versus 5 months, p=0.05) and equal to the dBMA Tregs ≥ 21/μL group (5 versus 5 months, p=0.902), respectively. The possible prognostic value of such an immunological player as BMA Tregs in the diagnostic and successive phases of AML needs to be confirmed in larger patient numbers.
format Article
id doaj-art-71d2e50a8dd04981b380485b378d829e
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-71d2e50a8dd04981b380485b378d829e2025-02-03T01:03:23ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/93252619325261Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia PatientsMario Delia0Paola Carluccio1Anna Mestice2Claudia Brunetti3Francesco Albano4Giorgina Specchia5Hematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyHematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyHematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyHematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyHematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyHematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyAcute myeloid leukemia (AML) is widely considered a distinct clinical entity with a well-defined molecular and genetics-based prognosis. Particularly in a younger patient, the therapeutic approach depends largely on diagnostic risk stratification, which has an impact on the outcome after therapy. We added Treg evaluation to the usual molecular and cytogenetics profile in the AML younger patients’ diagnostic bone marrow aspirate (dBMA) in order to search for any correlation between Tregs and overall response (OR) as well as survival (OS) rates. We studied 23 AML young patients, all treated with standard induction chemotherapy: OR (complete remission (CR) + CR incomplete (CRi)) was documented in 10 of 23 patients (44%); there were two partial responder patients. The optimal dBMA Treg cut-off value for predicting response to treatment (≥21/μL) was obtained by ROC curve analysis. However, in multivariate analysis, apart from the expected impact of the molecular/cytogenetic risk (p=0.049) and NPM mutation (p=0.001), dBMA Tregs ≥ 21/μL was not correlated with OR. Actually, higher dBMA Tregs were associated with the good intermediate molecular/cytogenetic risk group (p=0.02), whose median OS was confirmed to be better as compared with that of the poor risk group (18 versus 5 months, p=0.05) and equal to the dBMA Tregs ≥ 21/μL group (5 versus 5 months, p=0.902), respectively. The possible prognostic value of such an immunological player as BMA Tregs in the diagnostic and successive phases of AML needs to be confirmed in larger patient numbers.http://dx.doi.org/10.1155/2018/9325261
spellingShingle Mario Delia
Paola Carluccio
Anna Mestice
Claudia Brunetti
Francesco Albano
Giorgina Specchia
Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
Journal of Immunology Research
title Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
title_full Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
title_fullStr Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
title_full_unstemmed Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
title_short Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
title_sort impact of bone marrow aspirate tregs on the response rate of younger newly diagnosed acute myeloid leukemia patients
url http://dx.doi.org/10.1155/2018/9325261
work_keys_str_mv AT mariodelia impactofbonemarrowaspiratetregsontheresponserateofyoungernewlydiagnosedacutemyeloidleukemiapatients
AT paolacarluccio impactofbonemarrowaspiratetregsontheresponserateofyoungernewlydiagnosedacutemyeloidleukemiapatients
AT annamestice impactofbonemarrowaspiratetregsontheresponserateofyoungernewlydiagnosedacutemyeloidleukemiapatients
AT claudiabrunetti impactofbonemarrowaspiratetregsontheresponserateofyoungernewlydiagnosedacutemyeloidleukemiapatients
AT francescoalbano impactofbonemarrowaspiratetregsontheresponserateofyoungernewlydiagnosedacutemyeloidleukemiapatients
AT giorginaspecchia impactofbonemarrowaspiratetregsontheresponserateofyoungernewlydiagnosedacutemyeloidleukemiapatients